Veeva二季度业绩超预期并上调全年指引，盘后大涨约9%

Nvidia Q2 revenue more than doubles, CEO Huang says AI at its ’inflection point’
Introduction & Market Context
Veeva Systems (NYSE:VEEV) presented its fiscal second quarter 2027 results on August 26, 2026, showcasing performance that exceeded Wall Street expectations and prompted management to raise its full-year outlook. The life sciences software company reported total revenue of $928 million for the quarter ended July 31, representing 18% year-over-year growth, while maintaining robust operating margins above 44%. The strong results drove shares up 9.43% to $268 in after-hours trading, recovering from a regular session close of $244.91.
The quarter reflected broad-based strength across Veeva’s commercial and R&D software portfolios, with particular momentum in customer relationship management (CRM) solutions and services revenue. Management characterized the period as "our best CRM quarter ever," with execution across multiple product lines contributing to the beat on both revenue and earnings.
Quarterly Performance Highlights
As shown in the following breakdown of quarterly revenue trends, Veeva delivered consistent acceleration across its business segments in Q2’27.
Total revenue of $928 million for the second quarter represented an 18% increase from the $789 million reported in the year-ago period. The performance exceeded the consensus analyst estimate of $905.4 million by $22.6 million, or 2.5%. Subscription revenue, which accounts for approximately 83% of total revenue, reached $767 million, growing 16% year-over-year. Services revenue showed particular strength at $161 million, accelerating to 24% growth compared to 13% in the prior-year quarter.
The company’s adjusted earnings per share of $2.35 surpassed expectations of $2.22, representing a beat of $0.13 or 5.9%. This outperformance reflected both revenue strength and continued operational discipline, as the company maintained its non-GAAP operating margin at 44.8% for the quarter.
Management highlighted record performance in its commercial CRM business, noting wins with major pharmaceutical companies including Eli Lilly, Biogen, and Regeneron. The company now counts more than 180 Vault CRM customers live on its platform. Commercial subscription revenue grew 13% year-over-year, with double-digit growth maintained even when excluding the Crossix acquisition.
Profitability & Margin Expansion
The following chart illustrates Veeva’s quarterly operating income progression, demonstrating consistent profitability improvement.
Non-GAAP operating income for Q2’27 reached $416 million, up from $353 million in the year-ago quarter. The company has maintained operating margins in a tight range between 43.8% and 45.0% over the past five quarters, reflecting management’s strategy of balancing growth investments with profitability targets.
Looking at the annual trajectory, Veeva’s operating margin expansion has been substantial over the past several years.
Annual non-GAAP operating income grew from $759 million in fiscal 2022 to $1,434 million in fiscal 2026, with margins expanding from 41.0% to 44.9% over that period. The company’s fiscal 2027 guidance calls for approximately $1,640 million in non-GAAP operating income at roughly 44% margins, suggesting management expects to sustain current profitability levels while continuing to invest in growth initiatives.
The company’s cash generation capabilities have strengthened alongside operating performance, as demonstrated in the annual operating cash flow trends.
Non-GAAP operating cash flow reached $1,390 million in fiscal 2026, representing a 43% margin. For fiscal 2027, management guides to approximately $1,600 million in non-GAAP operating cash flow, maintaining the 43% margin profile. The company’s cash position has grown substantially, with cash, cash equivalents, and short-term investments reaching $6.6 billion at the end of fiscal 2026.
Revenue Growth Trajectory
The historical annual revenue progression provides context for Veeva’s sustained growth momentum.
Total revenue has nearly doubled from $1,851 million in fiscal 2022 to $3,195 million in fiscal 2026, representing a compound annual growth rate of approximately 15%. Subscription revenue has grown from $1,484 million to $2,684 million over the same period, while services revenue expanded from $367 million to $511 million.
The company’s fiscal 2027 guidance calls for total revenue between $3,682 million and $3,687 million, representing approximately 15% growth. This includes subscription revenue of roughly $3,080 million (15% growth) and services revenue of $602-607 million (19% growth at the midpoint).
Management noted that foreign exchange rates are expected to provide a tailwind of approximately $20 million to total revenue in fiscal 2027 compared to fiscal 2026, though the impact on operating income and normalized billings is expected to be immaterial.
Forward-Looking Statements
The company’s detailed fiscal 2027 guidance reflects confidence in sustained execution across its business.
For the full fiscal year ending January 31, 2027, Veeva expects total revenue of $3,682-3,687 million, with commercial subscription revenue of approximately $1,405 million and R&D and quality subscription revenue of roughly $1,675 million. Non-GAAP fully diluted net income per share is guided to approximately $9.21, while normalized billings are expected to reach around $3,870 million, representing 14% growth.
The normalized billings metric, which adjusts for timing changes in customer renewals and billing frequencies, is expected to be approximately $38 million below calculated billings in fiscal 2027. This adjustment reflects management’s effort to provide investors with a clearer view of underlying business momentum independent of billing timing variations.
For the immediate next quarter, management provided the following outlook.
Third quarter fiscal 2027 guidance calls for total revenue of $932-935 million, with subscription revenue of approximately $782 million and services revenue of $150-153 million. Non-GAAP operating income is expected to reach $417-420 million, translating to roughly 45% operating margins. Non-GAAP fully diluted net income per share is guided to $2.33-2.34 for the quarter ending October 31, 2026.
Management noted that current foreign exchange rates are expected to have an immaterial impact on both total revenue and non-GAAP operating income in the third quarter compared to the year-ago period.
Strategic Business Developments
Beyond the quarterly numbers, management highlighted several strategic initiatives during the earnings discussion. The company is advancing Falcon, described as an "agentic labor" product representing a new category beyond traditional cloud software and data consulting. Five early adopters are currently engaged, with first go-lives expected during fiscal 2027.
In the CRM space, management sees continued opportunity for market share gains and potential customer win-backs from Salesforce, particularly as some large customers that previously chose competing solutions have encountered implementation challenges. The company’s R&D portfolio is transitioning from legacy products such as eTMF, CTMS, and QualityDocs to next-generation offerings including EDC, eCOA, RTSM, Safety, and LIMS, which management views as larger long-term opportunities.
The company also introduced Aspen, a horizontal CRM product aimed at technology startups, though management emphasized this remains early-stage and is not incorporated into current revenue plans. Additionally, the relationship with IQVIA, a key partner in the life sciences data ecosystem, has strengthened significantly according to management commentary.
Market Reaction & Valuation Context
The market’s response to Veeva’s quarterly results and raised guidance was decisively positive. After closing the regular session at $244.91, down 0.76% on the day, shares surged 9.43% to $268 in after-hours trading. This move pushed the stock closer to the upper end of its 52-week range of $148.05 to $310.50.
According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform’s fair value estimate suggesting upside potential. The company maintains a market capitalization of approximately $39.85 billion and earns an overall "GREAT" financial health score. Over the past six months, Veeva shares have delivered a 34% return.
The combination of a solid earnings beat, revenue beat, and raised full-year outlook reinforced investor confidence in the company’s execution capabilities. For a software company of Veeva’s scale and maturity, sustaining mid-teens revenue growth while maintaining operating margins above 44% represents strong performance, particularly given the company’s ongoing investments in new product categories and market expansion initiatives.
The life sciences industry backdrop remains relatively stable despite broader macroeconomic and geopolitical uncertainties, with customers continuing to prioritize spending on digital engagement, data, and AI-related tools—areas where Veeva maintains strong positioning.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.